The estimated Net Worth of David R Bethune is at least $501 ezer dollars as of 31 October 2018. David Bethune owns over 140,000 units of Veru Inc stock worth over $501,104 and over the last 19 years David sold VERU stock worth over $0.
Sign up
David Bethune VERU stock SEC Form 4 insiders trading
David has made over 2 trades of the Veru Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently David exercised 140,000 units of VERU stock worth $121,800 on 31 October 2018.
The largest trade David's ever made was exercising 140,000 units of Veru Inc stock on 31 October 2018 worth over $121,800. On average, David trades about 8,353 units every 140 days since 2005. As of 31 October 2018 David still owns at least 575,982 units of Veru Inc stock.
You can see the complete history of David Bethune stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's David Bethune's mailing address?
David's mailing address filed with the SEC is ONE MEADOWLANDS PLAZA, , EAST RUTHERFORD, NJ, 07073.
Insiders trading at Veru Inc
Over the last 7 years, insiders at Veru Inc have traded over $5,672,221 worth of Veru Inc stock and bought 673,267 units worth $1,199,518 . The most active insiders traders include Mitchell Shuster Steiner, Harry Fisch és K Gary Barnette. On average, Veru Inc executives and independent directors trade stock every 33 days with the average trade being worth of $22,682. The most recent stock trade was executed by Harry Fisch on 24 May 2024, trading 4,000 units of VERU stock currently worth $5,000.
What does Veru Inc do?
the female health company/veru healthcare is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. to realize this goal, veru healthcare has three divisions: pharmaceutical and devices, consumer health products, and public sector. for men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout, and sexual dysfunction. women’s health has product candidates for female sexual health and advanced breast and ovarian cancers and markets fc2, a disposable contraceptive device, to ob gyn physicians and is the only female condom approved by fda that offers dual protection against sexually transmitted infections, including hiv/aids and the zika virus, and unintended pregnancy. since the female health company began distributing fc2 in 2007, the product has been shipped to 144 countries
What does Veru Inc's logo look like?
Complete history of David Bethune stock trades at Veru Inc
Veru Inc executives and stock owners
Veru Inc executives and other stock owners filed with the SEC include:
-
Dr. Mitchell S. Steiner F.A.C.S, F.A.C.S., M.D.,
Chairman, Pres & CEO -
Dr. Mitchell S. Steiner F.A.C.S., M.D., F.A.C.S,
Chairman, Pres & CEO -
Mitchell Steiner,
Chairman of the Board, President, Chief Executive Officer -
Dr. Harry Fisch F.A.C.S., M.D.,
Vice Chairman & Chief Corp. Officer -
K Barnette,
Chief Scientific Officer -
Michele Greco,
Chief Financial Officer, Chief Administrative Officer -
Dr. K. Gary Barnette Ph.D.,
Chief Scientific Officer -
Dr. Harry Fisch,
Vice Chairman & Chief Corp. Officer -
Harry Fisch,
Vice Chairman of the Board, Chief Corporate Officer -
Michele Greco,
CFO & Chief Admin. Officer -
Mario Eisenberger,
Independent Director -
Jesus Socorro,
Independent Director -
Michael Rankowitz,
Independent Director -
Joel Batten,
Exec. VP & GM of Infectious Disease Franchise -
Dr. Gary Bird Ph.D.,
Exec. VP of Quality & Regulatory Affairs -
Dr. Domingo Rodriguez M.D.,
Exec. VP of Global Clinical Operations -
Phillip Kuhn,
Exec. VP of Strategy & Commercial -
Philip R. Greenberg,
Exec. VP & Gen. Deputy Counsel -
Dr. Robert H. Getzenberg Ph.D.,
Exec. VP for Medical Affairs -
Kevin J. Gilbert CPA, J.D.,
Exec. VP of Corp. Devel. -
Michael J. Purvis,
Exec. VP, Gen. Counsel & Corp. Strategy -
Samuel Fisch,
Exec. Director of Investor Relations & Corp. Communications -
Loren Mark Katzovitz,
Director -
Brian J. Groch,
Chief Commercial Officer -
Daniel Haines,
Chief Financial Officer -
Grace Hyun,
Director -
Charles T Jr Todd,
CEO of FHC Division -
O B Parrish,
Director -
Lucy Lu,
Director -
Robert Getzenberg,
Chief Scientific Officer -
Mary Margaret Frank,
Director -
David R Bethune,
Director